Our present findings raise the possibility that, at least in a subset of breast cancer patients, CTGF might contribute to the process of breast cancer progression by allowing the development of ERα-negative phenotypes through reduction of ERα expression and repression of ER transcriptional activity, resulting in enhanced aggressiveness of breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.